121 related articles for article (PubMed ID: 36058521)
21. The association of proton pump inhibitors and hypomagnesemia in the community setting.
Markovits N; Loebstein R; Halkin H; Bialik M; Landes-Westerman J; Lomnicky J; Kurnik D
J Clin Pharmacol; 2014 Aug; 54(8):889-95. PubMed ID: 24771616
[TBL] [Abstract][Full Text] [Related]
22. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia.
Yin OQ; Giles FJ; Baccarani M; le Coutre P; Chiparus O; Gallagher N; Saglio G; Hughes TP; Hochhaus A; Kantarjian HM; Larson RA
Cancer Chemother Pharmacol; 2012 Aug; 70(2):345-50. PubMed ID: 22623211
[TBL] [Abstract][Full Text] [Related]
23. A pragmatic assessment of proton pump inhibitors vs. histamine type 2 receptor antagonists on clinically important gastrointestinal bleeding and mortality when used for stress ulcer prophylaxis in the ICU.
Boyd C; Hassig T; MacLaren R
Pharmacotherapy; 2021 Oct; 41(10):820-827. PubMed ID: 34478588
[TBL] [Abstract][Full Text] [Related]
24. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
25. Proton Pump Inhibitor and Histamine-2 Receptor Antagonist Use and Iron Deficiency.
Lam JR; Schneider JL; Quesenberry CP; Corley DA
Gastroenterology; 2017 Mar; 152(4):821-829.e1. PubMed ID: 27890768
[TBL] [Abstract][Full Text] [Related]
26. Proton pump inhibitors versus histamine-2 receptor blockers for stress ulcer prophylaxis in patients with sepsis: a retrospective cohort study.
Huang M; Han M; Han W; Kuang L
J Int Med Res; 2021 Jun; 49(6):3000605211025130. PubMed ID: 34182815
[TBL] [Abstract][Full Text] [Related]
27. The Association of Long-Term Use of Proton Pump Inhibitors and Histamine H
Gao J; Ma S; Xu S; Chen M
Dis Markers; 2022; 2022():4093595. PubMed ID: 35801003
[TBL] [Abstract][Full Text] [Related]
28. Histamine-2 receptor antagonists vs proton pump inhibitors on gastrointestinal tract hemorrhage and infectious complications in the intensive care unit.
MacLaren R; Reynolds PM; Allen RR
JAMA Intern Med; 2014 Apr; 174(4):564-74. PubMed ID: 24535015
[TBL] [Abstract][Full Text] [Related]
29. Proton Pump Inhibitors and Risk of Cardiovascular Disease: A Self-Controlled Case Series Study.
Park JY; Yoo J; Jeon J; Kim J; Kang S
Am J Gastroenterol; 2022 Jul; 117(7):1063-1071. PubMed ID: 35505518
[TBL] [Abstract][Full Text] [Related]
30. Association of Proton Pump Inhibitors Usage with Risk of Pneumonia in Dementia Patients.
Ho SW; Teng YH; Yang SF; Yeh HW; Wang YH; Chou MC; Yeh CB
J Am Geriatr Soc; 2017 Jul; 65(7):1441-1447. PubMed ID: 28321840
[TBL] [Abstract][Full Text] [Related]
31. Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.
Song TJ; Kim J
PLoS One; 2019; 14(5):e0216750. PubMed ID: 31067267
[TBL] [Abstract][Full Text] [Related]
32. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists.
Houben E; Johansson S; Nagy P; Penning-van Beest FJA; Kuipers EJ; Herings RMC
Curr Med Res Opin; 2018 Apr; 34(4):577-583. PubMed ID: 29149805
[TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor and histamine-2 receptor antagonist use and risk of liver cancer in two population-based studies.
Tran KT; McMenamin ÚC; Hicks B; Murchie P; Thrift AP; Coleman HG; Iversen L; Johnston BT; Lee AJ; Cardwell CR
Aliment Pharmacol Ther; 2018 Jul; 48(1):55-64. PubMed ID: 29741272
[TBL] [Abstract][Full Text] [Related]
34. Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression.
Cholin L; Ashour T; Mehdi A; Taliercio JJ; Daou R; Arrigain S; Schold JD; Thomas G; Nally J; Nakhoul NL; Nakhoul GN
BMC Nephrol; 2021 Jul; 22(1):264. PubMed ID: 34266395
[TBL] [Abstract][Full Text] [Related]
35. Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases.
Mitsuboshi S; Hamano H; Kuniki Y; Niimura T; Chuma M; Ushio S; Lin TJ; Matsumoto J; Takeda T; Kajizono M; Zamami Y; Ishizawa K
Ann Pharmacother; 2023 Nov; 57(11):1255-1263. PubMed ID: 36847276
[TBL] [Abstract][Full Text] [Related]
36. Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD.
Xie Y; Bowe B; Li T; Xian H; Balasubramanian S; Al-Aly Z
J Am Soc Nephrol; 2016 Oct; 27(10):3153-3163. PubMed ID: 27080976
[TBL] [Abstract][Full Text] [Related]
37. Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.
Shin GY; Park JM; Hong J; Cho YK; Yim HW; Choi MG
Am J Gastroenterol; 2021 Jun; 116(6):1211-1219. PubMed ID: 34074826
[TBL] [Abstract][Full Text] [Related]
38. Pneumonia prevention in intubated patients given sucralfate versus proton-pump inhibitors and/or histamine II receptor blockers.
Grindlinger GA; Cairo SB; Duperre CB
J Surg Res; 2016 Dec; 206(2):398-404. PubMed ID: 27884335
[TBL] [Abstract][Full Text] [Related]
39. Histamine-2 Receptor Antagonists and Proton Pump Inhibitors Are Associated With Reduced Risk of SARS-CoV-2 Infection Without Comorbidities Including Diabetes, Hypertension, and Dyslipidemia: A Propensity Score-Matched Nationwide Cohort Study.
Kim B; Jung JH; Han K; Kang S; Lee E; Chung H; Kim SG; Cho SJ
J Korean Med Sci; 2023 Apr; 38(13):e99. PubMed ID: 37012686
[TBL] [Abstract][Full Text] [Related]
40. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury.
Xie Y; Bowe B; Li T; Xian H; Yan Y; Al-Aly Z
Kidney Int; 2017 Jun; 91(6):1482-1494. PubMed ID: 28237709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
